FES PET/MRI Trial Targets Hidden Disease in Lobular Breast Cancer
Invasive lobular carcinoma often slips past standard breast imaging because its growth pattern is diffuse, subtle, and easy to misread as benign tissue distortion or scattered density rather than a discrete mass. The new FES PET/MRI study at the University of Wisconsin, Madison is built around that problem. Investigators plan to test whether fluorine 18 fluoroestradiol, or 18F-FES, can reveal occult disease after standard-of-care imaging has already been completed.
This is a prospective, single-arm diagnostic accuracy study enrolling 30 adults assigned female sex at birth with newly diagnosed invasive lobular carcinoma. Participants will undergo the PET/MRI examination after routine preoperative workup, then proceed to breast surgery or biopsy as clinically planned. The central question is straightforward and clinically consequential: can an estrogen receptor-targeted imaging agent identify disease that conventional mammography, ultrasound, and breast MRI leave behind?
Why Lobular Histology Creates a Staging Problem
Lobular tumors behave differently from ductal cancers at the bedside and on imaging. They are frequently estrogen receptor-positive, which gives 18F-FES a biologic foothold; the tracer binds estrogen receptors expressed on tumor cells and can map ER-positive sites throughout the body. In practice, that means the scan is not just looking for an anatomic lesion. It is interrogating receptor biology, which may be especially useful in a cancer subtype that can infiltrate breast tissue in a thin, linear, and geographically deceptive fashion.
One sentence captures the clinical stakes: occult disease changes surgery.
If PET/MRI identifies multifocal, multicentric, contralateral, nodal, or distant involvement that standard imaging missed, a patient initially headed for breast-conserving surgery could be redirected toward mastectomy, neoadjuvant therapy, or a different axillary approach. The protocol explicitly measures those management shifts, including conversion from curative to palliative intent when unsuspected metastatic disease appears, and conversion to neoadjuvant therapy when locally advanced disease is uncovered.
How the Imaging Strategy Is Built
Participants will receive an intravenous dose of approximately 6 millicuries of 18F-FES ±20 percent, administered contralateral to the primary tumor site, followed by PET/MRI. Gadolinium-based contrast is also part of the MRI component. The scan is designed to fuse metabolic receptor imaging with high-resolution soft tissue anatomy, a combination that matters in lobular cancer because tumor extent can be underestimated when anatomy is judged alone.
The study is not simply asking whether the scan lights up. It is asking whether the scan changes truth at several levels: lesion detection, tumor sizing, staging, and treatment planning. Investigators will compare imaging findings against histopathology, which serves as the reference standard. Primary outcome assessment centers on the percent of participants in whom disease is detected using 18F-FES-PET/MRI compared with disease found on tissue examination, a direct way to estimate sensitivity for occult lesions hidden on standard imaging.
A Study Design Focused on Real-World Surgical Decisions
Eligibility criteria keep the population tightly defined. Participants must have newly diagnosed lobular breast cancer confirmed on core-needle biopsy with at least 1 percent ER staining, must already have undergone or be scheduled for standard imaging, and must be planning surgery within 12 months of diagnosis. The study excludes prior ipsilateral axillary node dissection, recent anti-estrogen therapy, pregnancy or breastfeeding, known hypersensitivity to gadolinium-based contrast, and MRI contraindications such as inability to fit safely in the scanner.
The imaging readout goes beyond binary detection. Secondary endpoints include positive predictive value, the proportion of participants who are upstaged on TNM criteria, the frequency of multifocal, multicentric, or contralateral disease, and agreement between imaging-estimated tumor size and pathology. Investigators also plan to measure the error rate in size estimation between radiology and pathology for the primary lobular lesion. Those comparisons matter because underestimation of tumor span can lead to inadequate margins, re-excision, or a surgical plan that no longer fits the true disease burden.
Biological Rationale Behind the Tracer
The scanner’s advantage is tied to tumor receptor expression. 18F-FES is an estrogen analog, and its uptake should reflect estrogen receptor abundance rather than nonspecific contrast enhancement. That makes the agent biologically appealing in lobular cancers, which are commonly ER-positive and may therefore display enough receptor density to be visualized more clearly than with size-based imaging alone.
The exploratory objectives push that biology even further. Investigators will correlate standardized uptake value maximum, or SUVmax, with immunohistochemical quantification of ER expression and with cellularity. They also aim to define an SUVmax threshold for pathology-confirmed ER-positive lobular disease. If a clean threshold emerges, the scan could become more than a staging adjunct; it could become a functional bridge between receptor biology and operative planning.
What the Trial Could Clarify for Patients and Surgeons
The study is modest in size, with an estimated 30 participants and a follow-up window of up to six months, but its clinical reach is broader than the enrollment number suggests. Lobular breast cancer frequently complicates decisions about mastectomy versus breast conservation, and it can hide additional breast foci or extra-breast spread that change the entire treatment plan. A receptor-targeted PET/MRI approach may help resolve those uncertainties before the first incision is made.
The trial also has a practical limitation built into its own structure: it is a single-arm diagnostic study without a randomized comparator, and it will rely on histopathology as the standard against which imaging performance is judged. The sample size is small, so the estimates of sensitivity, predictive value, and staging change will need cautious interpretation. Even so, the study is well positioned to answer a focused question in a disease known for imaging ambiguity: how often does 18F-FES PET/MRI reveal clinically meaningful lobular breast cancer that standard workup leaves unseen?
For now, that remains the issue most worth watching as the first participants move toward enrollment in Madison.